Fat Grafting in the GLP-1 Era

Fat grafting is an integral part of facial plastic surgery. In some procedures it is a finishing touch. In others, particularly lower blepharoplasty, restoring or preserving volume is central to a natural result.

Recently, GLP-1 medications have certainly changed the way many patients lose weight. A few examples of these medications are Ozempic and Wegovy (semaglutide) or Zepbound and Mounjaro (tirzepatide). A fairly high percentage of patients presenting for facial surgery are taking one of these medications for weight management, and many intend to continue them long term. This is no longer a niche group: a KFF Health Tracking Poll in late 2025 found roughly one in eight US adults currently taking one of these medications.

That raises a question for the surgeon: what happens to fat we deliberately place in the face when the patient’s body is simultaneously being encouraged to lose fat?

The answer is not entirely straightforward. A fat graft is living tissue, and its survival depends first on establishing a blood supply. Once it survives, however, it remains responsive to the patient’s overall energy balance, which GLP-1 medications strongly influence.

For years, the questions around facial surgery were remarkably consistent: How many days will I be off work? How much bruising will I have? When can I get back to the gym?

Those still matter. But the widespread use of GLP-1 medications has added a new one to the consultation: when should I restart my medication?

Just a few years back the discussion about GLP-1s and fat grafting was different. A December 2024 member survey by the American Academy of Facial Plastic and Reconstructive Surgery reported a substantial increase in fat grafting procedures over the prior year, and nearly half of respondents reported seeing patients seeking treatment for facial changes associated with weight loss medications.

Ironically, the discussion has now flipped. These medications are not only bringing people to the operating room; a huge share of patients are already on one. While they are seeking surgery for reasons other than fat loss restoration, managing the medication’s postoperative effects has now become part of delivering a good result.

Fat grafting involves harvesting a small amount of a patient’s own fat, usually from the abdomen or thigh, processing it, and placing it into carefully selected areas of the face for a tasteful addition of volume.

The anatomy behind this is well mapped. The face carries its fat in distinct superficial and deep compartments, and as we age these compartments lose volume, descend, or change independently. Restoring volume to the right compartment is therefore an important part of restoring facial proportion. In a facelift, fat grafting is often a refinement. The facelift provides the structural work, repositioning and tightening the deeper tissues of the face and neck, while fat restores volume to the cheek, temple, or pre-jowl region. A facelift without fat grafting can still be an excellent operation; fat simply addresses a different component of facial aging.

Lower blepharoplasty is different. The aging lower eyelid is a game of shadows and volume. Historically, lower blepharoplasty meant removing the fat that created the bags, which alone could produce another problem: a hollow, skeletonized lower eyelid that can look more aged, and more operated, than the original bags. Over time we learned that redistribution of the fat in the lower eye and cheek provides the most natural and refreshed result. Modern lower blepharoplasty therefore emphasizes preserving, repositioning, or restoring volume. The goal is a smooth transition between the lower eyelid and cheek. In that setting, fat is not the polish on the operation. It is fundamental to the result, and fat grafting is the workhorse in accomplishing it.

GLP-1 medications are remarkably effective tools for weight management. They reduce appetite and food intake and alter several aspects of glucose and energy metabolism. The resulting caloric deficit causes the body to mobilize stored fat.

There is nothing wrong with this process. I am not advocating for these medications or against them; many patients simply find them well suited to their lifestyle and goals.

The important point for facial surgery is that the fat loss is systemic, not targeted. The body does not know that a particular pocket of fat is aesthetically important to a surgeon. As overall body fat decreases, facial fat decreases with it, and the same compartments we spend considerable effort restoring surgically can lose volume as weight continues to fall.

This is where fat grafting becomes biologically interesting. Unlike an off the shelf hyaluronic acid filler, a fat graft is living tissue. The moment it leaves the donor site (abdomen or thigh) it loses its blood supply and enters a state of hypoxia. Once transferred to its new home in the face, it begins the work of reestablishing a blood supply to stay alive.

For the first several days the graft survives largely on diffusion of oxygen and nutrients from the surrounding recipient tissue, a process called imbibition. Small vessels from the recipient bed then connect with vessels in the graft, a process called inosculation, and new vessels subsequently grow into and throughout the graft through angiogenesis. The goal is a mature microvascular network that gives the transplanted tissue a durable blood supply.

The early period is a race between the graft’s ability to survive on diffusion and the recipient tissue’s ability to establish vascular support. This part of the story affects everyone, and it is why smokers and diabetics make poor candidates for fat grafting. But after this initial life or death period, the next phase of graft healing is where a GLP-1 can affect the final result.

This is the question almost every patient asks: how much will take?

The honest answer is that there is no single percentage. Reported long term retention after facial fat grafting varies with technique, recipient site, the amount and distribution of fat, how retention is measured, and the biology of the individual patient. That variability exists even when everything is done well.

One thing that does reliably affect take is losing weight after the procedure. This is the most important concept for patients taking a GLP-1 medication. Transplanted fat is not a permanent implant. It is living tissue, and once it establishes a blood supply it behaves, in many respects, like fatty tissue elsewhere in the body. If the patient gains weight, grafted fat can enlarge. If the patient loses weight, grafted fat can shrink.

This means a graft can take beautifully, heal normally, and still lose volume months later if the body is subsequently placed into a sustained caloric deficit. This was simply not a factor we had to weigh as recently as three to five years ago.

This is where the science becomes less definitive.

There is no high quality clinical trial establishing a restart date for GLP-1 therapy after facial fat grafting. We know that early graft survival depends on revascularization and that the graft remodels for months, but we do not have evidence that restarting at one particular week changes long term retention by a particular amount.

So this is ultimately a clinical judgment. My first thought is always why the patient is taking the medication. A GLP-1 prescribed for diabetes cannot be interrupted on the same terms as one used for elective weight maintenance. In those cases the patient’s health background and the prescribing physician’s input matter.

The next question I consider is the weight trajectory. There is a meaningful difference between a patient at a stable weight and one still planning to lose twenty or thirty more pounds. Grafting volume into a face that is still losing volume is building on moving ground, and I do not recommend it. Waiting until a stable weight is reached before surgery with fat grafting is the best path for the patient.

If the weight is stable and we are doing fat grafting, I generally discuss waiting at least one month after fat grafting before restarting a GLP-1. That is based on my clinical experience and an understanding of graft physiology. It is a practical compromise between allowing the graft to establish itself and respecting the other lifestyle goals the patient may have.

The best candidate for substantial fat grafting is someone whose weight is reasonably stable, particularly patients using a GLP-1 at a low maintenance dose or only occasionally. I am more cautious when a patient is:

• still in the middle of significant weight loss,
• actively titrating a GLP-1 medication,
• planning to lose substantial additional weight,
• anticipating a prolonged period of caloric restriction,
• or dealing with compromised wound healing, as in smoking or diabetes.

Being a less than ideal candidate for fat grafting does not mean facial surgery has to wait. In lower blepharoplasty, the patient’s own orbital fat can often be preserved and repositioned, restoring the lid-cheek transition. Hyaluronic acid fillers and other bio-stimulatory treatments can also be useful adjuncts in blepharoplasty or facelift procedures. They have their own advantages and limitations, but unlike autologous fat grafting, their volume does not fluctuate with weight changes.

The choice is not fat grafting versus no surgery. It is choosing the method of volume restoration that fits that specific person.

GLP-1 medications have changed the landscape of weight management, and their influence now extends into facial plastic surgery in multiple ways.

They are not incompatible with fat grafting. But fat grafting and weight loss are biologically pulling in opposite directions. One asks the body to establish and maintain new adipose volume in a particular location. The other asks it to reduce fat throughout the body, including the tissue we just placed in the face.

If you take a GLP-1 medication and are considering facial surgery, particularly a procedure that relies on fat grafting, tell your surgeon. In the GLP-1 era, the technique of fat grafting has not fundamentally changed, but the metabolic environment in which we perform it has.